The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T cell lymphoma patients

類似資料

• Inhibition of Cell-Mediated Immunity by the Histone Deacetylase Inhibitor Vorinostat:Implications for Therapy of Cutaneous T-Cell Lymphoma
  著者:: Stephen, Sasha, 等
  出版事項: (2011)
• Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
  著者:: Sager, Philip T, 等
  出版事項: (2015)
• Increased Programmed Death-1 Expression on CD4(+) T Cells in Cutaneous T-Cell Lymphoma: Implications for Immune Suppression
  著者:: Samimi, Sara, 等
  出版事項: (2010)
• The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells
  著者:: Tiffon, CE, 等
  出版事項: (2011)
• Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
  著者:: Piekarz, Richard L., 等
  出版事項: (2009)